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Abstract
© 2015  Bentham Science  Publishers.  Amyotrophic  lateral  sclerosis  (ALS)  is  an  incurable,
chronic, fatal neuro-degenerative disease characterized by progressive loss of moto-neurons
and  paralysis  of  skeletal  muscles.  Reactivating  dysfunctional  areas  is  under  earnest
investigation utilizing various approaches. Here we present an innovative gene-cell construct
aimed at reviving inert  structure and function.  Human umbilical  cord blood cells  (hUCBCs)
transduced with adeno-viral vectors encoding human VEGF, GDNF and/or NCAM genes were
transplanted  into  transgenic  ALS  mice  models.  Significant  improvement  in  behavioral
performance (open-field and grip-strength tests), as well as increased life-span was observed in
rodents  treated  with  NCAM-VEGF  or  NCAM-GDNF  co-transfected  cells.  Active  trans-gene
expression was found in the spinal cord of ALS mice 10 weeks after delivering genetically
modified hUCBCs, and cells were detectable even 5 months following transplantation. Our gene-
cell  therapy model  yielded prominent  symptomatic  control  and prolonged life-time in  ALS.
Incredible  survivability  of  xeno-transpanted  cells  was  also  observed  without  any  immune-
suppression.  These  results  suggest  that  engineered  hUCBCs  may  offer  effective  gene-cell
therapy in ALS.
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